The latest developments across the GLP-1 landscape, from new drug approvals and clinical research to pricing changes and policy shifts. Stay informed on the updates that affect Ozempic, Wegovy, Mounjaro, and the wider category.
News & Updates
The GLP-1 medication boom isn't just attracting pharmaceutical companies anymore. Major technology players are positioning themselves to capitalize on the weight loss drug wave—and for patients currently on or considering GLP-1 therapy, that shift could matter more than you think.
Novo Nordisk just announced positive results from its PIONEER TEENS trial, testing oral semaglutide in children and adolescents with type 2 diabetes. If approved, it could be the first oral GLP-1 medication available for kids ages 10–17. Here's what the data means and why it matters.
The Trump administration has quietly pulled the plug on a Medicare pilot program that would have expanded access to GLP-1 weight loss medications for seniors. If you're on Medicare and counting on that coverage, here's what you need to know — and what your options actually are.
South Korea's Ministry of Food and Drug Safety has officially designated Wegovy and Mounjaro as drugs with abuse concerns. This doesn't mean these medications are dangerous or being banned — but it does signal something worth understanding if you're on GLP-1 therapy.
Amazon has entered the GLP-1 medication space, promising fast and convenient access to weight loss drugs like semaglutide and tirzepatide. For people already navigating this therapy—or considering it—the news raises real questions. Here's an honest look at what this program means for patients.
Injectable GLP-1 medications have dominated the weight loss and diabetes space, but oral options are gaining serious ground. New developments in drug delivery technology are pushing the boundaries of what's possible in pill form. Here's what you need to know as a patient.
7 essential supplements to prevent nutrient loss on GLP-1 drugs.
GLP-1 safety for seniors plus Medicare 2026 coverage rules.
.avif)
%20(1).avif)